|
|
|
|
|
Highlights from the American Society of Radiation Oncology (ASTRO) Annual Meeting
|
|
|
|
|
State of the Art Selection and Treatment of Localized Prostate Cancer
|
|
| Transcriptomic Analysis of ATM Expression in Localized Prostate Cancer – Implications for Radiotherapy Treatment
|
| Karthik Meiyappan, BS
|
| The 2022 ASTRO Annual Meeting was host to a State of the Art session for the selection and treatment of localized prostate cancer. Karthik Meiyappan presented transcriptomic analysis of ATM expression in localized prostate cancer and its implications for radiotherapy treatment. The authors hypothesized that higher ATM expression is a predictor of differential outcomes after radiotherapy.
|
|
|
|
|
|
| Patient Reported Quality of Life after Moderately Hypofractionated Proton Beam Therapy or Intensity Modulated Radiation Therapy for Prostate Cancer
|
| Alexander Lukez, MD
|
| During the State of the Art session for the selection and treatment of localized prostate cancer, Dr. Alexander Lukez presented results of a study evaluating patient reported quality of life after moderately hypofractionated proton beam therapy or intensity modulated radiation therapy for prostate cancer. The authors sought to characterize and compare late GI and GU patient-reported outcomes between patients treated with either proton beam therapy or IMRT.
|
|
|
|
|
|
| Superior Post-Treatment Biopsy Outcomes with High Dose SBRT Compared to High-Dose Conventionally Fractionated IMRT for Clinically Localized Prostate Cancer
|
| Michael J. Zelefsky, MD
|
| During the State of the Art session for the selection and treatment of localized prostate cancer, Dr. Michael Zelefsky presented results of a study evaluating post-treatment biopsy outcomes with high dose SBRT compared to high-dose conventionally fractionated intensity-modulation radiation therapy (IMRT) for clinically localized prostate cancer. The purpose of this study was to retrospectively compare post-treatment biopsy outcomes of prostate cancer patients treated with high-dose conventionally fractionated IMRT versus high dose SBRT.
|
|
|
|
|
|
|
|
|
|
|
| MRI-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE): Primary Endpoint Analysis of a Phase III Randomized Trial
|
| Amar U. Kisha, MD
|
| During the State of the Art session for the selection and treatment of localized prostate cancer, Dr. Amar Kishan presented the primary endpoint analysis of MIRAGE: a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy for prostate cancer. The study hypothesis was that aggressive margin reduction from 4 to 2 mm using MR-guided radiotherapy technology would reduce acute grade 2+ GU toxicity from 29% to 14%.
|
|
|
|
|
|
| Toxicity and Patient Reported Quality of Life Outcomes Following Prostate SBRT with Focal Boost to MRI Identified Prostate Cancer Lesions: Results of a Phase II Trial
|
| Brett A. Morris, MD
|
| The State of the Art session for the selection and treatment of localized prostate cancer included a presentation by Dr. Brett Morris discussing results of a phase II trial evaluating the toxicity and patient reported quality of life outcomes following prostate SBRT with focal boost to MRI identified prostate cancer lesions. The authors sought to evaluate whether heterogenous radiation therapy to the prostate with focal boost would provide a similar favorable toxicity profile without compromising oncologic outcomes.
|
|
|
|
|
|
|
Posters - Genitourinary Cancer, Patient Safety, and Nursing
|
|
| The Maximum Standardized Uptake Value in Patients with Recurrent or Persistent Prostate Cancer after Radical Prostatectomy and PSMA-PET-Guided Salvage Radiotherapy – A Multicenter Retrospective Analysis
|
| Simon K. B. Spohn, MD
|
| In this presentation, Dr. Simon Spohn discussed the maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy. Dr. Spohn and colleagues evaluated the association of the maximum standardized uptake value (SUVmax) in positron-emission tomography targeting PSMA-PET prior to salvage radiotherapy on biochemical recurrence free survival in a large multicenter cohort.
|
|
|
|
|
|
| Using Molecular Imaging to Create Guidelines for the Optimal Clinical Target Volume for Para-Aortic Lymph Nodes in Prostate Cancer
|
| Anjali Saripalli, MD
|
| During this presentation by Dr. Anjali Saripalli, he discussed using molecular imaging to create guidelines for the optimal clinical target volume for para-aortic lymph nodes. The objective of this study presented by Dr. Saripalli and colleagues is to use molecular imaging to develop guidelines for contouring the para-aortic clinical target volume in patients with prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Challenges and Solutions During the COVID Pandemic for Patient Retention and Physician Engagement in the Phase 3 ATLAS Study of Apalutamide Added to ADT in High-Risk Localized or Locally Advanced Prostate Cancer
|
| Howard M. Sandler, MD
|
| In this presentation, Dr. Howard Sandler discussed challenges and solutions during the COVID pandemic for patient retention and physician engagement in the phase 3 ATLAS study of apalutamide added to ADT in high-risk localized or locally advanced prostate cancer. Dr. Sandler and colleagues described initiatives used for patient and physician participation, noting specific challenges related to patient retention during the COVID-19 pandemic, while maintaining trial integrity.
|
|
|
|
|
|
| Single Fraction HDR Brachytherapy for Prostate Cancer: SiFEPI Phase II Trial Results
|
| Nina Pujol, MD
|
| In this presentation, Dr. Nina Pujol discussed the Single Fraction Early Prostate Irradiation (SiFEPI) phase II trial assessing single fraction high-dose rate (HDR) brachytherapy for prostate cancer. Dr. Pujol and colleagues conducted the SiFEPI phase 2 prospective trial.
|
|
|
|
|
|
| The Proportion of Prostate Cancer Randomized Control Trials Involving Radiation Therapy over Time
|
| Suvidya L. Pachigolla, MD
|
| In this presentation, Suvidya Pachigolla discussed the proportion of prostate cancer randomized clinical trials involving radiation therapy over time. The primary purpose of this study presented at ASTRO 2022 was to quantify the proportion of prostate cancer randomized clinical trials involving radiation therapy over time.
|
|
|
|
|
|
| Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer
|
| Abdenour Nabid, MD
|
| In this presentation, Dr. Abdenour Nabid discussed cardiovascular causes of death in patients treated for localized prostate cancer. From two trials in localized prostate cancer, cardiovascular disease represented the second cause of death. Based on Dr. Nabid and colleagues’ data, they retrieved and reviewed the clinical information on those patients labelled by investigators as dying from cardiovascular disease aiming to confirm and precisely define the cause/diagnosis of their cardiovascular death.
|
|
|
|
|
|
| Patterns of Care after 68Ga-PSMA-PET in Patients with Radiorecurrent Localized Only Prostate Cancer
|
| Krystal A. Morales Rivera, MD, PhD
|
| In this presentation, Dr. Krystal Morales Rivera discussed patterns of care after 68Ga-PSMA-PET in patients with radio recurrent localized only prostate cancer. Dr. Morales Rivera and colleagues sought to evaluate patterns of care in these men, in order to understand the referral patterns and care plans implemented as a result of molecular imaging.
|
|
|
|
|
|
|
